Th Pathways in Immune-Mediated Skin Disorders: A Guide for Strategic Treatment Decisions

키워드

참고문헌 (145)

1. Pawlak M, "Cytokines and transcription factors in the differentiation of CD4+ T helper cell subsets and induction of tissue inflammation and autoimmunity", Curr Opin Immunol, 67, pp.57~67 (2020)
2. Ho AW, "T cells and the skin : from protective immunity to inflammatory skin disorders", Nat Rev Immunol, 19, pp.490~502 (2019)
3. Kortekaas Krohn I, "T-cell subsets in the skin and their role in inflammatory skin disorders", Allergy, 77, pp.827~842 (2022)
4. Harris JE, "A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin", J Invest Dermatol, 132, pp.1869~1876 (2012)
5. Freyschmidt-Paul P, "Interferon-gamma-deficient mice are resistant to the development of alopecia areata", Br J Dermatol, 155, pp.515~521 (2006)
6. Bradley LM, "A direct role for IFN-gamma in regulation of Th1 cell development", J Immunol, 157, pp.1350~1358 (1996)
7. Kang S, "Direct antiviral mechanisms of interferon-gamma", Immune Netw, 18, pp.e33~ (2018)
8. Sareneva T, "IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells", J Immunol, 165, pp.1933~1938 (2000)
9. Waldmann TA, "The biology of interleukin-2 and interleukin-15 : implications for cancer therapy and vaccine design", Nat Rev Immunol, 6, pp.595~601 (2006)
10. Kalia V, "Regulation of effector and memory CD8 T cell differentiation by IL-2-A balancing act", Front Immunol, 9, pp.2987~ (2018)
11. Waldmann TA, "The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes : implications for cancer therapy", Cancer Immunol Res, 3, pp.219~227 (2015)
12. Finkelman FD, "The other side of the coin : the protective role of the TH2 cytokines", J Allergy Clin Immunol, 107, pp.772~780 (2001)
13. Howell MD, "Modulation of filaggrin by Th2 cytokines in the skin of atopic dermatitis(AD)", J Allergy Clin Immunol, 119, pp.S283~ (2007)
14. Tazawa T, "Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis", Arch Dermatol Res, 295, pp.459~464 (2004)
15. Zhu J, "T helper 2(Th2)cell differentiation, type 2 innate lymphoid cell(ILC2)development and regulation of interleukin-4(IL-4)and IL-13 production", Cytokine, 75, pp.14~24 (2015)
16. Punnonen J, "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells", Proc Natl Acad Sci U S A, 90, pp.3730~3734 (1993)
17. Gieseck RL 3rd, "Type 2 immunity in tissue repair and fibrosis", Nat Rev Immunol, 18, pp.62~76 (2018)
18. Speeckaert R, "The many faces of interleukin-17 in inflammatory skin diseases", Br J Dermatol, 175, pp.892~901 (2016)
19. Amatya N, "IL-17 signaling : the yin and the yang", Trends Immunol, 38, pp.310~322 (2017)
20. Nies JF, "IL-17C", IL-17RE : emergence of a unique axis in TH17 biology, 2020, pp.11, 341~
21. Ge Y, "Biology of interleukin-17 and its pathophysiological significance in sepsis", Front Immunol, 11, pp.1558~ (2020)
22. Huangfu L, "The IL-17 family in diseases : from bench to bedside", Signal Transduct Target Ther, 8, pp.402~ (2023)
23. Borowczyk J, "IL-17E(IL-25)and IL-17A differentially affect the functions of human keratinocytes", J Invest Dermatol, 140, pp.1379~1389 (2020)
24. Stritesky GL, "IL-23 promotes maintenance but not commitment to the Th17 lineage", J Immunol, 181, pp.5948~5955 (2008)
25. Tollenaere MA, "Signalling of multiple interleukin(IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways", Br J Dermatol, 185, pp.585~594 (2021)
26. Lauffer F, "IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema", J Eur Acad Dermatol Venereol, 34, pp.800~809 (2020)
27. Borowczyk J, "IL-25(IL-17E)in epithelial immunology and pathophysiology", J Allergy Clin Immunol, 148, pp.40~52 (2021)
28. Walker LS, "The link between circulating follicular helper T cells and autoimmunity", Nat Rev Immunol, 22, pp.567~575 (2022)
29. Ma CS, "The origins, function, and regulation of T follicular helper cells", J Exp Med, 209, pp.1241~1253 (2012)
30. Speeckaert R, "A meta-analysis of chemokines in vitiligo : recruiting immune cells towards melanocytes", Front Immunol, 14, pp.1112811~ (2023)
31. Zainodini N, "Differential expression of CXCL1, CXCL9, CXCL10 and CXCL12 chemokines in alopecia areata", Iran J Immunol, 10, pp.40~46 (2013)
32. Hsueh YC, "A keratinocyte-tethered biologic enables location-precise treatment in mouse vitiligo", J Invest Dermatol, 142, pp.3294~3303 (2022)
33. Valsecchi R, "Alopecia areata and interleukin-2 receptor", Dermatology, 184, pp.126~128 (1992)
34. Speeckaert R, "Clinical significance of serum soluble CD molecules to assess disease activity in vitiligo", JAMA Dermatol, 152, pp.1194~1200 (2016)
35. Montilla AM, "Scoping review on the use of drugs targeting JAK", STAT pathway in atopic dermatitis, vitiligo, and alopecia areata, 2019, pp.9, 655~683
36. Speeckaert R, "Biomarkers of disease activity in vitiligo : a systematic review", Autoimmun Rev, 16, pp.937~945 (2017)
37. Passeron T, "Inhibition of T-cell activity in alopecia areata : recent developments and new directions", Front Immunol, 14, pp.1243556~ (2023)
38. Lauffer F, "Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis", J Invest Dermatol, 138, pp.1785~1794 (2018)
39. Solimani F, "Therapeutic targeting of Th17", Tc17 cells leads to clinical improvement of lichen planus, 2019, pp.10, 1808~
40. Pietschke K, "The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibition", Exp Dermatol, 30, pp.262~270 (2021)
41. Tan YQ, "Increased circulating CXCR5+ CD4+ T follicular helper-like cells in oral lichen planus", J Oral Pathol Med, 46, pp.803~809 (2017)
42. Wang H, "IL-25 promotes Th2-type reactions and correlates with disease severity in the pathogenesis of oral lichen planus", Arch Oral Biol, 98, pp.115~121 (2019)
43. Terlou A, "An autoimmune phenotype in vulvar lichen sclerosus and lichen planus : a Th1 response and high levels of microRNA-155", J Invest Dermatol, 132, pp.658~666 (2012)
44. Wang L, "Transcriptome profiling and network analysis provide insights into the pathogenesis of vulvar lichen sclerosus", Front Genet, 13, pp.905450~ (2022)
45. Peterson DM, "Treatment of lichen sclerosus and hypertrophic scars with dupilumab", JAAD Case Rep, 23, pp.76~78 (2022)
46. Muhammad Yusoff F, "Th1, Th2, and Th17 cytokines in systemic lupus erythematosus", Autoimmunity, 53, pp.8~20 (2020)
47. Nakayamada S, "Clinical relevance of T follicular helper cells in systemic lupus erythematosus", Expert Rev Clin Immunol, 17, pp.1143~1150 (2021)
48. Bitar C, "Apremilast as a potential treatment for moderate to severe dermatomyositis : a retrospective study of 3 patients", JAAD Case Rep, 5, pp.191~194 (2019)
49. Shimojima Y, "Phenotypes of peripheral blood lymphocytes and cytokine expression in polymyositis and dermatomyositis before treatment and after clinical remission", Clin Med Insights Arthritis Musculoskelet Disord, 5, pp.77~87 (2012)
50. Broos CE, "Increased T-helper 17. 1 cells in sarcoidosis mediastinal lymph nodes", Eur Respir J, 51, pp.1701124~ (2018)
51. Bordignon M, "Adaptive immune responses in primary cutaneous sarcoidosis", Clin Dev Immunol, 2011, pp.235142~ (2011)
52. Zhou ER, "Key players and biomarkers of the adaptive immune system in the pathogenesis of sarcoidosis", Int J Mol Sci, 21, pp.7398~ (2020)
53. Antiga E, "T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum", Clin Exp Immunol, 189, pp.383~391 (2017)
54. Flora A, "Pyoderma gangrenosum : a systematic review of the molecular characteristics of disease", Exp Dermatol, 31, pp.498~515 (2022)
55. Min MS, "Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways", J Am Acad Dermatol, 83, pp.63~70 (2020)
56. Paganini C, "Letter in response to the case report : "recalcitrant generalized granuloma annulare treated successfully with dupilumab"", JAAD Case Rep, 39, pp.152~154 (2023)
57. Orfali RL, "Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis", Pharmaceutics, 15, pp.577~ (2023)
58. Li H, "Update on the pathogenesis and therapy of atopic dermatitis", Clin Rev Allergy Immunol, 61, pp.324~338 (2021)
59. Noda S, "The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization", J Allergy Clin Immunol, 136, pp.1254~1264 (2015)
60. Leonard A, "The unique molecular signatures of contact dermatitis and implications for treatment", Clin Rev Allergy Immunol, 56, pp.1~8 (2019)
61. Nosbaum A, "Allergic and irritant contact dermatitis", Eur J Dermatol, 19, pp.325~332 (2009)
62. Chen Q, "Different expression patterns of plasma Th1-, Th2-, Th17-and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria", J Eur Acad Dermatol Venereol, 32, pp.441~448 (2018)
63. LaChance AH, "Immunologic underpinnings and treatment of morphea", Expert Rev Clin Immunol, 18, pp.461~483 (2022)
64. Shao Y, "Molecular mechanisms of pruritus in prurigo nodularis", Front Immunol, 14, pp.1301817~ (2023)
65. Park K, "Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo", Eur J Dermatol, 21, pp.135~136 (2011)
66. Belzberg M, "Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization", J Invest Dermatol, 141, pp.2208~2218 (2021)
67. Bachelez H, "Interleukin 23 inhibitors for psoriasis : not just another number", Lancet, 390, pp.208~210 (2017)
68. Hu P, "The role of helper T cells in psoriasis", Front Immunol, 12, pp.788940~ (2021)
69. Gu H, "Participation of interferons in psoriatic inflammation", Cytokine Growth Factor Rev, 64, pp.12~20 (2022)
70. Qu Y, "Transcriptional regulation on effector T cells in the pathogenesis of psoriasis", Eur J Med Res, 28, pp.182~ (2023)
71. Kelhälä HL, "IL-17", Th17 pathway is activated in acne lesions, 2014, pp.9, e105238~
72. Kistowska M, "Propionibacterium acnes promotes Th17 and Th17", Th1 responses in acne patients, 2015, pp.135, 110~118
73. Buhl T, "Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1", Th17 pathways, 2015, pp.135, 2198~2208
74. Heibel HD, "Rosacea associated with dupilumab therapy", J Dermatolog Treat, 32, pp.114~116 (2021)
75. Li Q, "Follicular helper T cells(Tfh)and IL-21 involvement in the pathogenesis of bullous pemphigoid", PLoS One, 8, pp.e68145~ (2013)
76. Huang R, "Study of cytokine-induced immunity in bullous pemphigoid : recent developments", Ann Med, 55, pp.2280991~ (2023)
77. Plée J, "Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome", Sci Rep, 5, pp.18001~ (2015)
78. Hennerici T, "Increased frequency of t follicular helper cells and elevated interleukin-27 plasma levels in patients with pemphigus", PLoS One, 11, pp.e0148919~ (2016)
79. Zou Y, "The pathogenic role of CD4+ tissue-resident memory T cells bearing t follicular helper-like phenotype in pemphigus lesions", J Invest Dermatol, 141, pp.2141~2150 (2021)
80. Holstein J, "Immunophenotyping in pemphigus reveals a TH17", TFH17 cell-dominated immune response promoting desmoglein1, J Allergy Clin Immunol, pp.2021, 147[DOI]
81. Kim AR, "Targeting inducible costimulator expressed on CXCR5+PD-1+ TH cells suppresses the progression of pemphigus vulgaris", J Allergy Clin Immunol, 146, pp.1070~1079 (2020)
82. Zhao Y, "Circulating T follicular helper cell and regulatory T cell frequencies are influenced by B cell depletion in patients with granulomatosis with polyangiitis", Rheumatology(Oxford), 53, pp.621~630 (2014)
83. Gensous N, "T follicular helper cells in autoimmune disorders", Front Immunol, 9, pp.1637~ (2018)
84. Sanders JSF, "The Th1 and Th2 paradigm in ANCA-associated vasculitis", Kidney Blood Press Res, 26, pp.215~220 (2003)
85. Liberman AC, "Regulatory and mechanistic actions of glucocorticoids on T and inflammatory cells", Front Endocrinol(Lausanne), 9, pp.235~ (2018)
86. van Geel N, "In vivo vitiligo induction and therapy model : double-blind, randomized clinical trial", Pigment Cell Melanoma Res, 25, pp.57~65 (2012)
87. Flores C, "Lessons to learn from low-dose cyclosporin-a : a new approach for unexpected clinical applications", Front Immunol, 10, pp.588~ (2019)
88. Thomas S, "Methotrexate is a JAK", STAT pathway inhibitor, 2015, pp.10, e0130078~
89. Gerards AH, "Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis", Rheumatology(Oxford), 42, pp.1189~1196 (2003)
90. Karnell JL, "Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation", J Immunol, 187, pp.3603~3612 (2011)
91. Heidt S, "Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help", Clin Exp Immunol, 159, pp.199~207 (2010)
92. Tiede I, "CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes", J Clin Invest, 111, pp.1133~1145 (2003)
93. Sulaimani J, "Dimethyl fumarate modulates the Treg-Th17 cell axis in patients with psoriasis", Br J Dermatol, 184, pp.495~503 (2021)
94. Holm Hansen R, "Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis", Mult Scler, 25, pp.1289~1297 (2019)
95. In ’t Veld AE, "Immunosuppression by hydroxychloroquine : mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study", Immunol Res, 71, pp.617~627 (2023)
96. Han J, "Novel function of hydroxychloroquine : down regulation of T follicular helper cells in collagen-induced arthritis", Biomed Pharmacother, 97, pp.838~843 (2018)
97. Espinosa E, "Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases", Clin Immunol, 194, pp.75~79 (2018)
98. Gao W, "Biomarkers and biologics related with psoriasis and psoriatic arthritis", Int Immunopharmacol, 122, pp.110646~ (2023)
99. Calabrese L, "Therapeutic potential of IL-1 antagonism in hidradenitis suppurativa", Biomolecules, 14, pp.175~ (2024)
100. Yahyazadeh S, "Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls", Res Pharm Sci, 17, pp.315~323 (2022)
101. Kubo M, "T follicular helper and TH2 cells in allergic responses", Allergol Int, 66, pp.377~381 (2017)
102. Nebert DW, "Aryl hydrocarbon receptor(AHR) : "pioneer member"of the basic-helix", loop, PAS)family of"sensors"of foreign and endogenous signals, pp.Prog Lipid Res, 2017[DOI]
103. Esser C, "The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology", Pharmacol Rev, 67, pp.259~279 (2015)
104. Quintana FJ, "Aryl hydrocarbon receptor control of adaptive immunity", Pharmacol Rev, 65, pp.1148~1161 (2013)
105. Desai SR, "Tapinarof cream 1% once daily for the treatment of plaque psoriasis : case photography of clinical outcomes from three phase 3 trials", Dermatol Ther(Heidelb), 13, pp.2443~2460 (2023)
106. Fernández-Gallego N, "Role of AHR ligands in skin homeostasis and cutaneous inflammation", Cells, 10, pp.3176~ (2021)
107. Napolitano M, "Role of aryl hydrocarbon receptor activation in inflammatory chronic skin diseases", Cells, 10, pp.3559~ (2021)
108. Laouini D, "COX-2 inhibition enhances the TH2 immune response to epicutaneous sensitization", J Allergy Clin Immunol, 116, pp.390~396 (2005)
109. Hirata T, "Prostanoids as regulators of innate and adaptive immunity", Adv Immunol, 116, pp.143~174 (2012)
110. Dec M, "Aryl hydrocarbon receptor role in chronic inflammatory skin diseases : a narrative review", Postepy Dermatol Alergol, 41, pp.9~19 (2024)
111. Boniface K, "Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2", EP4 receptor signaling, 2009, pp.206, 535~548
112. Silverberg JI, "Pharmacology of orismilast, a potent and selective PDE4 inhibitor", J Eur Acad Dermatol Venereol, 37, pp.721~729 (2023)
113. Schafer PH, "Apremilast normalizes gene expression of inflammatory mediators in human keratinocytes and reduces antigen-induced atopic dermatitis in mice", Drugs R D, 19, pp.329~338 (2019)
114. Bianchi L, "Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis", Expert Opin Drug Metab Toxicol, 12, pp.1121~1128 (2016)
115. Schafer PH, "Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis", Br J Pharmacol, 159, pp.842~855 (2010)
116. Carmona-Rocha E, "New and emerging oral", topical small-molecule treatments for psoriasis, 2024, pp.16, 239~
117. McLornan DP, "Current and future status of JAK inhibitors", Lancet, 398, pp.803~816 (2021)
118. Tanaka Y, "Janus kinase-targeting therapies in rheumatology : a mechanisms-based approach", Nat Rev Rheumatol, 18, pp.133~145 (2022)
119. Martin DA, "Target occupancy and functional inhibition of JAK3 and TEC family kinases by ritlecitinib in healthy adults : an open-label, phase 1 study", J Clin Pharmacol, 64, pp.67~79 (2024)
120. "A phase 2 multicenter, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of lutikizumab (ABT-981) in adult subjects with moderate to severe hidradenitis suppurativa who have failed anti-TNF therapy: amended protocol to include a lutikizumab open-label sub-study in subjects naïve to biologic therapy"[URL]
121. Fleischmann RM, "A phase II trial of lutikizumab, an anti-interleukin-1α", β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis, 2019, pp.71, 1056~1069
122. Teufel LU, "IL-1 family cytokines as drivers and inhibitors of trained immunity", Cytokine, 150, pp.155773~ (2022)
123. Tuttle J, "A phase 2 trial of peresolimab for adults with rheumatoid arthritis", N Engl J Med, 388, pp.1853~1862 (2023)
124. Scully M, "32nd EADV Congress 2023" (2023), EADV
125. Gilfillan AM, "The tyrosine kinase network regulating mast cell activation", Immunol Rev, 228, pp.149~169 (2009)
126. Aoki Y, "Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells", Proc Natl Acad Sci U S A, 91, pp.10606~10609 (1994)
127. Neys SFH, "Targeting Bruton’s tyrosine kinase in inflammatory and autoimmune pathologies", Front Cell Dev Biol, 9, pp.668131~ (2021)
128. Ellmeier W, "Tec family kinases : regulation of FcεRI-mediated mast-cell activation", FEBS J, 278, pp.1990~2000 (2011)
129. Xing Y, "Preclinical mechanisms of topical PRN473, a Bruton tyrosine kinase inhibitor, in immune-mediated skin disease models", Immunohorizons, 5, pp.581~589 (2021)
130. Mendes-Bastos P, "Bruton’s tyrosine kinase inhibition-an emerging therapeutic strategy in immune-mediated dermatological conditions", Allergy, 77, pp.2355~2366 (2022)
131. Vinuesa CG, "Follicular helper T cells", Annu Rev Immunol, 34, pp.335~368 (2016)
132. Spolski R, "Interleukin-21 : a double-edged sword with therapeutic potential", Nat Rev Drug Discov, 13, pp.379~395 (2014)
133. Caprioli F, "Autocrine regulation of IL-21 production in human T lymphocytes", J Immunol, 180, pp.1800~1807 (2008)
134. Mesas-Fernández A, "Interleukin-21 in autoimmune and inflammatory skin diseases", Eur J Immunol, 53, pp.e2250075~ (2023)
135. Brunner PM, "Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab", J Allergy Clin Immunol, 143, pp.142~154 (2019)
136. Nakashima C, "Interleukin-31 and interleukin-31 receptor : new therapeutic targets for atopic dermatitis", Exp Dermatol, 27, pp.327~331 (2018)
137. Lé AM, "OX40-OX40L inhibition for the treatment of atopic dermatitis-focus on rocatinlimab and amlitelimab", Pharmaceutics, 14, pp.2753~ (2022)
138. Fu N, "The OX40", OX40L axis regulates T follicular helper cell differentiation : implications for autoimmune diseases, 2021, pp.12, 670637~
139. Khoryati L, "An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice", Sci Immunol, 5, pp.eaba5264~ (2020)
140. Richmond JM, "Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo", Sci Transl Med, 10, pp.eaam7710~ (2018)
141. Zhu LN, "FcRn inhibitors : a novel option for the treatment of myasthenia gravis", Neural Regen Res, 18, pp.1637~1644 (2023)
142. Maho-Vaillant M, "FcRn antagonism leads to a decrease of desmoglein-specific B cells : secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus", Front Immunol, 13, pp.863095~ (2022)
143. Guttman-Yassky E, "Phase 2a randomized clinical trial of dupilumab(anti-IL-4Rα)for alopecia areata patients", Allergy, 77, pp.897~906 (2022)
144. Datsi A, "Interleukin-31 : the"itchy"cytokine in inflammation and therapy", Allergy, 76, pp.2982~2997 (2021)
145. Langenberg C, "Biological and functional multimorbidity-from mechanisms to management", Nat Med, 29, pp.1649~1657 (2023)

관련 논문AI추천